President Donald Trump has achieved nine new pricing agreements with drug manufacturers aimed at decreasing prescription medication costs in the U.S. These agreements reflect his commitment to reducing patient expenses through negotiations with pharmaceutical firms.
Trump’s strategy of negotiating with companies on a case-by-case basis is commendable. However, addressing the underlying issue of high drug prices involves tackling the free-riding practices of foreign countries that benefit from American drug innovation without sharing the associated costs.
To achieve sustainable price reductions while maintaining U.S. leadership in biomedical innovation, the Trump administration must concentrate its efforts on negotiating with other nations to ensure they contribute fairly to the development costs of new medications.
Foreign Pricing Practices
For many years, affluent countries have implemented policies such as price controls, mandatory rebates, and reimbursement delays. These tactics suppress their payment for cutting-edge medications, allowing them to benefit from innovations while Americans bear a majority of the development costs. U.S. consumers make up approximately three-quarters of pharmaceutical profits and over half of global research and development expenditure.
Instead of exerting more pressure on U.S. drugmakers, American leaders should focus on compelling other countries to cease their free-riding practices. Implementing proposals like the ‘most-favored-nation’ pricing might harm American patients and the biotech industry by importing foreign price controls into the U.S., reducing funding for research, and threatening industry jobs.
If other affluent countries paid U.S. prices for new drugs, global pharmaceutical revenue could increase significantly, bolstering American drug innovation and creating jobs.
To uphold both lower prices and ongoing innovation domestically, wealthier countries must contribute more substantially to research costs.
Global Negotiations and Agreements
The Trump administration’s proven negotiation skills present an opportunity to press foreign governments to reform their pricing policies. For instance, a recent agreement with the United Kingdom obligates Britain to raise payments for new medications by 25%, thereby decreasing the overall financial burden on the U.S.
The administration is also pursuing a similar arrangement with Germany. In June, officials initiated an investigation into German drug price controls, providing leverage for negotiating equitable pricing practices with German policymakers.
The administration aims to apply this negotiation strategy to other wealthy nations like Japan, France, and Switzerland, which employ tactics similar to Germany’s. In Japan, nearly half of newly introduced medications face annual price cuts.
Trump’s administration is determined to reduce drug prices by leveraging its negotiating power to procure concessions from countries benefiting from U.S. innovations without paying their fair share.
By intensified negotiations with trading partners, the Trump administration can contribute to lowering drug prices for American patients while securing the U.S. biopharmaceutical industry’s leadership.
Ambassador Jeffrey Gerrish served as the Deputy U.S. Trade Representative from 2018 to 2020.
Leave a Reply